AHA Scientific Sessions 2023 Late-Breaking Science Coverage

Published: 30 October 2023

  • Views:

    Views Icon 2243
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.

 

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.

 

Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

 

Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.

 

Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.

More from this programme

Part 1

View from the Thoraxcenter

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. 

Part 2

Late-Breaker Discussions with Harriette Van Spall

Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

About the episode

AHA 23 - We are joined on-site by Prof Uwe Zeymer (Klinikum Ludwigshafen, Ludwigshafen, DE) to discuss the findings from a sub-analysis of the ECLS-SHOCK trial.

This sub-analysis investigates the impact of cardiac arrest before randomisation on the efficacy of ECLS in patients with infarct-related cardiogenic shock. Investigators enrolled 420 patients with acute MI and cardiogenic shock across 41 centers. The primary outcome was 30-day mortality.

Investigators reached 49% mortality in the control group, however there was no reduction in mortality with implantation of a VA-ECMO device at 47.8%. Bleeding and vascular complications were higher regardless of whether patients had cardiac arrest before randomisation.

Interview Questions:

  1. What is the reasoning behind this sub-analysis?
  2. What was the patient population and study design?
  3. What were your key findings?
  4. What are your take-home messages?
  5. What further study is needed, and what are the next steps?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Interviewer: Mirjam Boros
Editor: Jordan Rance
Video Specialist: Dan Brent, Mike Knight, Tom Green

Faculty Biographies

Uwe Zeymer

Uwe Zeymer

Senior Cardiologist

Professor Uwe Zeymer is an interventional cardiologist at the Klinikum Ludwigshafen (Germany). His interests include acute cardiac care and acute coronary syndromes.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.